Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 13,615 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy; Procedure · Other · Genetic + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more

Conditions: Breast Cancer
Interventions: Everolimus, Fulvestrant; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 45 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions: Molecular Breast Imaging, Screening Mammography; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Progeria
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions: navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy; Biological
Lead sponsor: OncXerna Theraputics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more

Conditions: Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions: L-NMMA, Pembrolizumab; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more

Conditions: Atopic Dermatitis
Interventions: Oral DS107, Placebo; Drug
Lead sponsor: Dignity Sciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Arlington Heights, Illinois • West Dundee, Illinois • Warren, Michigan + 5 more

Conditions: Metastatic Breast Cancer
Interventions: Understanding value in Metastatic Breast Cancer; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 100 participants
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Skin Cancer, Signs and Symptoms
Interventions: Modulated Imaging (MI), Photodynamic therapy; Device · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Irvine, California

Conditions: Metastatic Breast Cancer
Interventions: Amrubicin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 28
States / cities: New Milford, Connecticut • Sharon, Connecticut • Torrington, Connecticut + 22 more

Conditions: Psoriasis
Interventions: Risankizumab, Autoinjector; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more

Conditions: Breast Cancer, Lymph Node Metastases
Interventions: SpotTM Tattoo Ink; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: Fecal Microbiota Transplant with Pembrolizumab; Drug
Lead sponsor: Zarour, Hassane, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI); Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Pembrolizumab, Quality-of-Life Assessment, Therapeutic Tumor Infiltrating Lymphocytes; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Pancreatic Ductal Adenocarcinoma, Progesterone Receptor Negative, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Lymphoma, Refractory Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions: Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions: Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri

Conditions: Melanoma
Interventions: Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity, Cardiovascular Diseases
Interventions: anonymized data collection during programmed surveillance clinical follow up; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Breast Cancer
Interventions: filgrastim, docetaxel, vinorelbine; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 99
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 61 more

Conditions: Atopic Dermatitis, Sleep Disturbance
Interventions: Dupilumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: bendamustine, erlotinib, Maintenance erlotinib; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Depression, Weight Changes
Interventions: Calcium-Rich Diet, Arm 2: Exercise + Calcium-Rich Diet, Exercise + Fruit & Vegetable, Low Fat + Calcium Diet; Dietary Supplement · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Durham, North Carolina • Goldsboro, North Carolina • Winston-Salem, North Carolina + 1 more

Search by objective public record fields.

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Molecular Breast Imaging in Women With Atypia and LCIS

Clinical Studies of Progeria

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Phase Ib of L-NMMA and Pembrolizumab

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Oral DS107 in Moderate to Severe Atopic Dermatitis

Understanding Value in Metastatic Breast Cancer

Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Axillary Lymph Node Tattoo Marking Study

Fecal Microbiota Transplant (FMT) in Melanoma Patients

Dendritic Cell Vaccination During Lymphoid Reconstruction

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

IACS-010759 in Advanced Cancers

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Global Cardio Oncology Registry

S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Survival TRaining for ENhancing Total Health (STRENGTH)